A. Fisher (Newcastle, United Kingdom), F. Meloni (Pavia, Italy)
A prospective, open-label pilot-study of azithromycin for lung allograft lymphocytic bronchiolitis: Preliminary results
R. Vos, B. Vanaudenaerde, S. Verleden, S. De Vleeschauwer, A. Willems-Widyastuti, A. Schoonis, D. Van Raemdonck, L. Dupont, G. Verleden (Leuven, Belgium)
|  |
Analysis of exhaled breath condensate cytokine pattern in lung transplant recipients with and without BOS
B. Antus, I. Barta, K. Czebe, I. Horvath, E. Csiszer (Budapest, Törökbalint, Hungary)
|  |
Crossing the divide between clinical BOS risk prediction and proteomic BALF biomarkers
T. Oumeraci, J. Gottlieb, T. Wolf, B. Brors, A. Pich, A. Haverich, R. Eils, B. Schlegelberger, T. Welte, M. Zapatka, N. von Neuhoff (Heidelberg, Germany)
|  |
BAL-fluid profile of several pro-inflammatory, Th1, Th2 and B cell related cytochines in BOS patients
V. Conio, N. Solari, M. Morosini, A. Grasso, A. Cascina, T. Oggionni, A. M. Fietta, F. Meloni (Pavia, Italy)
| |
Protein profiling in two different phenotypes of bronchiolitis obliterans syndrome after lung transplantation
S. E. Verleden, R. Vos, S. I. De Vleesschauwer, S. Willems, V. Mertens, A. Willems-Widyastuti, L. J. Dupont, B. M. Vanaudenaerde, G. M. Verleden, D. E. Van Raemdonck (Leuven, Belgium)
| |
Bile acid injury of airway epithelial cells before and after lung transplantation
A. Aseeri, M. Brodlie, J. Pearson, J. Lordan, J. Dark, P. Corris, C. Ward (Newcastle upon Tyne, United Kingdom)
| |
Towards a model of bronchiolitis obliterans syndrome in single lung transplanted mice
S. De Vleeschauwer, W. Jungraithmayr, S. Wauters, M. Rinaldi, R. Vos, S. Verleden, A. Willems-Widyastuti, E. Verbeken, B. Vanaudenaerde, D. Van Raemdonck, A. Boehler, W. Weder, G. Verleden (Leuven, Belgium; , Switzerland)
| |